Stem Cell Biology and Regenerative Medicine

Introduction to Stem Cell Biology

Stem cells are defined by two key properties: self-renewal—the ability to divide and produce identical daughter cells maintaining the stem cell pool—and potency—the ability to differentiate into specialised cell types. These properties, maintained by distinct molecular mechanisms, enable stem cells to sustain tissue homeostasis throughout life and respond to injury. Stem cell potency is hierarchical: totipotent cells (zygote) can form all embryonic and extraembryonic tissues; pluripotent cells (inner cell mass, embryonic stem cells) form all embryonic tissues; multipotent tissue-specific stem cells (haematopoietic, neural, gut) generate specific lineages.

Stem cell biology has been transformed by Shinya Yamanaka's 2006 discovery that adult somatic cells can be reprogrammed to induced pluripotent stem cells (iPSCs) by overexpressing just four transcription factors (Oct4, Sox2, Klf4, c-Myc). This Nobel Prize-winning discovery established that cell fate is reversible and epigenetically determined rather than irreversibly fixed, enabling patient-specific pluripotent cells without embryo destruction. iPSC technology has created disease modelling and drug testing platforms, personalised cell therapy approaches, and patient-specific organoids—three-dimensional tissue models recapitulating organ biology in vitro.

Embryonic Stem Cells

Pluripotency Networks

Embryonic stem cell (ESC) pluripotency is maintained by a core transcription factor network: OCT4, SOX2, and NANOG form an interconnected autoregulatory circuit activating their own expression and each other's while repressing differentiation genes. Target genes of the pluripotency network include both active genes required for ESC identity and bivalent genes—bearing both active H3K4me3 and repressive H3K27me3 marks—poised for activation upon differentiation. LIF-STAT3 and BMP-SMAD signalling maintain mouse ESC self-renewal; human ESCs require FGF and Activin/Nodal-SMAD2/3 signalling—a species difference reflecting distinct embryonic states.

Directed Differentiation of Pluripotent Cells

Directed differentiation protocols sequentially expose pluripotent cells to growth factors and small molecules mimicking embryonic development signals to generate specific cell types. Cardiomyocytes are derived through mesoderm induction (Wnt activation, BMP), cardiac mesoderm specification (Wnt inhibition, FGF), and cardiomyocyte maturation (21 days total). Pancreatic beta cells require six-stage differentiation (definitive endoderm, pancreatic progenitor, endocrine progenitor, beta cell) over 30-40 days. These protocols enable drug testing on disease-relevant human cell types, disease modelling in patient iPSC-derived cardiomyocytes, and eventually cell therapy applications.

Adult Stem Cells and Tissue Niches

Haematopoietic Stem Cells

Haematopoietic stem cells (HSCs) in adult bone marrow sustain lifelong blood cell production from a pool of ~10,000 HSCs. HSCs express EPCR, CD150, CD48- markers; they self-renew through asymmetric division and generate all blood lineages through hierarchical progenitor commitments. The bone marrow niche—osteoblasts, CXCL12-abundant reticular cells, sinusoidal endothelium, megakaryocytes, sympathetic nerves—provides signals (SCF, CXCL12, Ang-1, thrombopoietin) maintaining HSC quiescence and self-renewal. HSC transplantation (bone marrow transplantation) treats haematological malignancies and inherited disorders; editing patient HSCs with CRISPR to correct sickling mutations or reactivate fetal haemoglobin offers curative gene therapies.

Intestinal Stem Cells

The intestinal epithelium renews every 3-5 days, sustained by Lgr5+ crypt base columnar stem cells. Wnt signalling from crypt Paneth cells and stroma maintains stem cell identity; BMP gradient from villus tip to crypt base restricts stem cell zone to the bottom. Notch signalling regulates absorptive (goblet cell) versus secretory cell fate. Lgr5+ intestinal stem cells were the first adult stem cells grown in organoid culture—three-dimensional self-organising structures recapitulating crypt-villus architecture indefinitely in vitro using EGF, Noggin, and R-spondin (ENR cocktail). Intestinal organoids are used for drug testing, personalised medicine, disease modelling, and exploring regenerative capacity.

Organoids

Organoids are self-organising 3D tissue structures grown from pluripotent stem cells or adult tissue stem cells in extracellular matrix gels. Brain organoids developed during 40-70 days from iPSCs recapitulate cerebral cortical layering with progenitors, outer radial glia, and cortical neurons—modelling microcephaly, Zika virus brain pathology, and autism spectrum disorder in patient-specific models. Liver organoids from cholangiocytes and hepatocytes self-assemble with bile duct and parenchymal compartments modelling NASH, cholestatic disease, and drug toxicity. Kidney organoids contain nephrons (podocytes, tubular segment cells) useful for studying polycystic kidney disease mutations. Patient-derived tumour organoids predict chemotherapy response in clinical trials with patient matching.

Examples and Applications

Example 1: CRISPR Stem Cell Gene Therapy for Sickle Cell

Two CRISPR-based gene therapies (Casgevy and Lyfgenia) were approved in late 2023—the first approved CRISPR therapies. Casgevy (CTX001) edits BCL11A enhancer in patient HSCs to reactivate fetal haemoglobin (HbF), which does not sickle, providing long-term correction. In trials, all treated patients with sickle cell disease and beta-thalassaemia were free of vaso-occlusive crises at 12+ months. Lyfgenia inserts a corrected HBB gene using lentiviral vector. Both require autologous HSC harvesting, ex vivo editing, myeloablative conditioning, and reinfusion—a complex but potentially curative single treatment for diseases severely limiting quality of life.

Example 2: CAR-T Cell Therapy

CD19-specific CAR-T cells (chimeric antigen receptor T cells) genetically engineered from patient's own T cells have transformed treatment of B cell malignancies. In relapsed/refractory B-ALL, CD19 CAR-T achieved over 80% complete remission rates versus essentially 0% for chemotherapy. Axicabtagene ciloleucel and tisagenlecleucel are approved for B-ALL, DLBCL, follicular lymphoma, and multiple myeloma (BCMA CAR-T). Challenges include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), short persistence, antigen escape, and manufacturing complexity. Next-generation CAR-T improvements include allogeneic (universal donor) CAR-T, armoured CAR-T with additional co-stimulatory features, and CAR-NK cells.

Example 3: iPSC Disease Modelling

Patient-specific iPSC disease models enable study of human genetic diseases in relevant cell types with patient's actual mutation background. iPSC-derived cardiomyocytes from long QT syndrome patients with KCNQ1 mutations show extended action potentials; drug screening identified compounds reducing the QT prolongation phenotype. ALS patient iPSC-derived motor neurons show TDP-43 aggregation and axonal defects preceding cell death; compound screens identified candidates reducing TDP-43 pathology. iPSC models of schizophrenia show reduced synaptic density in cortical neurons correlating with symptom severity. The ability to derive any cell type from any patient's genetics is revolutionising disease biology research.

Example 4: Cerebral Organoids and Brain Development

Lancaster et al. 2013 demonstrated that iPSC-derived cerebral organoids spontaneously self-organise into cortical regions with venticular zones harbouring neural progenitors and outer cortical regions with neurons. MCPH1-mutant iPSC organoids showed the premature differentiation phenotype of microcephaly patients; Zika virus infected organoids showed the preferential killing of outer radial glia explaining microcephaly in congenital Zika infection—published in Science 2016 weeks after the outbreak, demonstrating organoid speed in addressing public health emergencies. Cortical organoid slices on multi-electrode arrays record spontaneous electrical activity, enabling electrophysiological phenotyping of brain diseases.

Example 5: Haematopoietic Stem Cell Transplantation

Allogeneic HSC transplantation cures haematological malignancies (AML, ALL, CML, lymphoma) by replacing cancerous haematopoiesis with donor cells providing graft-versus-leukaemia effect. HLA-matched donor selection determines graft-versus-host disease (GvHD) risk—T cells in donor marrow recognise host tissues as foreign. T cell depletion or post-transplant cyclophosphamide reduces GvHD; haploidentical (50% HLA-matched parent) transplantation is now feasible with improved GvHD prevention, dramatically expanding donor availability. Umbilical cord blood provides HLA-permissive alternative for patients without matched unrelated donors.

Example 6: Pancreatic Beta Cell Replacement

Type 1 diabetes results from autoimmune destruction of insulin-producing beta cells. Islet transplantation from cadaveric donors provides temporary insulin independence but requires lifelong immunosuppression and donor availability limits scale. Vertex Pharmaceuticals demonstrated that iPSC-derived functional islet cells (VX-880) transplanted into T1D patients restored glucose-responsive insulin secretion in early clinical trials—a landmark potential cure. Encapsulation devices protecting transplanted cells from immune destruction could eliminate immunosuppression requirements. Allogeneic iPSC-derived islets manufactured at scale could provide an unlimited supply, making this therapy broadly accessible if immunological challenges are solved.

Example 7: Skin Stem Cell Therapy

The epidermis is sustained by basal keratinocyte stem cells expressing p63, SOX9, and integrins. In severe burn patients lacking sufficient donor skin for grafting, cultured epithelial autografts (CEAs) grown ex vivo from small skin biopsies are life-saving. Gene therapy of keratinocyte stem cells with corrected laminin-332 gene restored skin integrity in junctional epidermolysis bullosa (JEB)—a painful blistering disease—transplanted across 80% body surface area in an Italian child (published 2017 in Nature). The patient's renewed skin showed normal durability 3+ years later, demonstrating that corrected stem cell grafts provide durable cure by regenerating normal tissue from genetically corrected precursors.

Example 8: Liver Organoid Transplantation

Cholangiopathy patients with bile duct loss (primary sclerosing cholangitis, biliary atresia) have few treatment options beyond liver transplantation. Prospective isolation of Lgr5+ liver stem cells enabling mass expansion followed by differentiation into cholangiocytes or hepatocytes modelled in organoids. Transplantation of human liver organoids into mouse models of liver disease repopulated the organ and restored function. Clinical trials of autologous corrected liver organoid transplantation in PFIC (progressive familial intrahepatic cholestasis) patients with corrected ATP8B1 gene, and allogenic liver organoid transplantation for acute-on-chronic liver disease, are enrolling—representing the frontier of therapeutic organoid applications.

Try it live

Everything above runs in your browser — open Stem Cell Lineage & Organoid Growth Explorer and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.